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A Stage-Specific Enhancer of Immunoglobulin
J Chain Gene Is Induced by Interleukin-2
in a Presecretor B Cell Stage
cell±specific activator protein, also known as Pax5) to
a repressor element located between base pairs 2126
and 2113 in the promoter (McFadden and Koshland,
1991; Rinkenberger et al., 1996). The interaction of BSAP
with this element mediates the silencing of the J chain
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Berkeley, California 94720±3200 gene during the early antigen-independent stages of B
cell development, and the repression is relieved during
the antigen-driven stages by an IL-2±induced down-
regulation of BSAP RNA expression (Rinkenberger et al.,Summary
1996). The BCL1 system has also been used to identify
a second target of IL-2/IL-5 regulation, the zinc fingerInterleukin-2 (IL-2)±induced transcription of the J
chain gene was used as a model for analyzing cytokine Blimp-1 nuclear protein (Turner et al., 1994). Transcripts
of the Blimp-1 gene are rapidly induced following IL-2regulation during B cell development. To determine
whether IL-2 signals are targeted to a J chain gene or IL-5 treatment, and their expression leads to the in-
duction of J chain message and a high level of IgMenhancer as well as to its promoter, the sequences
flanking the J chain gene were first examined for secretion. As yet, however, no direct interaction has
been demonstrated between Blimp-1 and J chain geneDNase I hypersensitivity. Of six sites identified, two
strong ones, 7.5 kb upstream of the J chain gene, were sequences.
In the present work, the analyses of this model werefound to be associated with an enhancer that is active
only during the antigen-driven stages of B cell devel- extended to determine whether the IL-2 signal is tar-
geted to a J chain gene enhancer as well as to its pro-opment. Further analyses of the enhancer in the IL-
2±responsive presecretor BCL1 cells showed that the moter. Transient transfection assays had shown the J
chain promoter itself had little or no detectable abilityenhancer is activated at this stage by an IL-2 signal
that functions by opening the enhancer chromatin and to drive expression of a reporter gene (Lansford et al.,
1992). It seemed likely, therefore, that J chain genestimulating STAT5 to bind to a STAT5 element critical
for the enhancer induction. Moreover, after this early activity was strongly dependent on an enhancer ele-
ment, as is the case for the genes encoding other immu-induction stage, the enhancer was shown to be consti-
tutively open and active in terminally differentiated noglobulin chains (Hagman et al., 1990; Henderson and
Calame, 1995). In this report, we describe the identifica-plasma cells.
tion of an enhancer sequence by examining the flanking
Introduction sequences of the J chain gene for DNase I hypersensi-
tive sites (HSSs) associated with J chain gene transcrip-
Expression of the J chain gene has provided a useful tion in plasma cell lines. We show that two strongly
model to analyze cytokine regulation of B cell antibody hypersensitive sites 7.5 kb upstream of the transcrip-
responses. The J chain gene is activated late ina primary tional start site are induced by IL-2 treatment of prese-
immune response by the binding of interleukin 2 (IL-2) cretor BCL1 cellsand that the sequence containing these
and/or IL-5 to high-affinity receptors expressed on anti- sites functions as a B cell±specific and developmentally
gen-stimulated B lymphoblasts (Nakanishi et al., 1984; regulated enhancer. Furthermore, we identify STAT5 (sig-
Matsui et al., 1989). The cytokine signals result in a rapid nal transducer and activator of transcription 5) as one
accumulation of J chain mRNA transcripts (Lamson and of the IL-2 targets regulating the induction of the J chain
Koshland, 1984) and subsequentsynthesis of theJ chain gene enhancer. Finally, we show that in terminally differ-
protein required for the assembly of pentamer immuno- entiated plasma B cells such as S194 and MOPC315,
globulin M (IgM) antibody (Niles et al., 1995). Moreover, the enhancer of the J chain gene is constitutively active
these events can be reproduced in vitro with presecretor in the absence of IL-2 and STAT5 stimulation.
lymphoid cell lines such as B cell leukemia 1 (BCL1) that
retain the ability to express high-affinity IL-2 and/or IL-5
Resultsreceptors (Brooks et al., 1983; Blackman et al., 1986).
Analyses of the BCL1 model have shown that IL-2 Identification of Six DNase I Hypersensitiveinduces two changes in the J chain gene promoter. One
Sites in the Upstream Region of theis an opening of the chromatin structure that extends
Expressed J Chain Geneapproximately 170 bp upstream of the transcriptional
As a first approach in locating the putative J chain en-start site (Minie and Koshland, 1986). A second is the
hancer, the flanking sequences of the active J chaindecreased binding of the transcription factor BSAP (B
gene were examined for DNase I hypersensitive sites
(HSSs). These sites provide indices of open chromatin
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betweeen HSSs 3, 4, 5, and 6 and J chain gene transcrip-
tion. The chromatin at these sites was completely resis-
tant to DNase I digestion in non-B cells; it became very
slightly DNase I sensitive in the WEHI231 and K46R cell
lines, representative of immature and mature B cells,
respectively; and it was readily accessible to DNase I
cleavage in the MPC11 and S194 cell lines, representative
of plasma cells expressing high levels of J chain (Figure
2A). Moreover, the pattern of chromatin changes in
the upstream HSSs 3, 4, 5, and 6 during B cell develop-
ment was identical to that previously shown to occur at
the HSS 1 site in the J chain gene promoter (Figure 2A)
(Minie and Koshland, 1986). In contrast, sites 2 and 7
were found to be independent of J chain gene expres-Figure 1. Identification of DNase I HSSs 59 of the Active J Chain
Gene sion. The weak HSS 2 was confined to B cells, but ap-
Nuclei from J chain±expressing S194 cells were subjected to time- peared in DNA from J chain±negative as well as J
dependent digestion with DNase I. The DNA was then extracted, chain±positive cells (data not shown). The relatively
secondarily digested with appropriate restriction enzymes, and strong HSS 7 was present in all lymphoid DNA examined
electrophoresed on 0.8% agarose gels. HSS 1 was mapped by
(Figure 2B).probing BamHI-digested DNA with a 600 bp EcoRI±BamHI sequence
from the 39 end of the 2.85 kb BamHI fragment; HSSs 2, 3, and
4 were identified by probing BamHI-digested DNA with a 165 bp
Regulation of HSSs 3 and 4 by IL-2BamHI±DraI sequence from the 59 terminus of the 8.2 kb BamHI
fragment; and HSSs 5 and 6 and HSS 7 were mapped by probing In previous studies, advantage was taken of the IL-2±
SpeI±XhoI±digested and XhoI-digested DNAs, respectively, with a inducible BCL1 cell line to demonstrate that treatment
310 bp sequence from the 39 terminus of the 23 kb XhoI fragment. with the cytokine induces chromatin changes in the J
The thick bars on the map represent the respective probes; the
chain promoter. The changes were manifest by the de-vertical arrows indicate the location of the HSSs, and their length
velopment of a DNase I HSS (HSS 1) (Minie and Kosh-is a rough measure of the degree of sensitivity; and the horizontal
land, 1986). The same system was used in the presentarrow indicates the transcriptional start site of the J chain gene. B,
BamHI; Sp, SpeI; and Xh, XhoI. study to assess a potential IL-2 responsiveness of the
HSSs. BCL1 cells were cultured for 2 days in the pres-
ence or absence of IL-2. Nuclei were harvested and
digestion with DNase I. The DNA was then extracted, subjected to time-dependent digestion with DNase I.
treated with appropriate restriction enzymes, and ana- Southern blotsof the DNase I±digested samples showed
lyzed in Southern blots with probes derived from the that HSSs 3 and 4 were just barely detectable in the
termini of the relevant restriction fragments. By this DNA from untreated BCL1 cells (Figure 2C). The finding
strategy, six DNase I HSSs were found to span a 16 kb that the chromatin in these cells was slightly accessible
sequence immediately 59 of the J chain gene promoter to DNase I attack was consistent with their presecretor
(Figure 1). The sites were designated HSSs 2±7; HSS 1 stage of development. In the DNA from IL-2±treated
was reserved for the nuclease hypersensitive site in- cells, however, HSSs 3 and 4 were very accessible to
duced in theJ chain gene promoter (Minieand Koshland, DNase I cleavage (Figure 2C), indicating that the cyto-
1986). No additional sites were detected in another 16 kine induced a complete opening of the chromatin.
kb of sequence upstream nor in 14 kb of sequence 39
to the J chain gene.
HSSs 2±7 were located by use of the BamHI and XhoI Enhancer Activity of the Sequences
Containing HSSs 3 and 4restriction enzymes and probes as illustrated in Figure
1. Mapping revealed that the sites were distributed in The function of the J chain±associated hypersensitive
sequences was evaluated by transient transfection anal-two groups and varied in susceptibility to DNase I diges-
tion. One group was located between 6 and 7.5 kb up- yses using a luciferase reporter construct containing 1.2
kb of J chain gene promoter sequence (Lansford et al.,stream of the transcriptional start site and consisted of
two very strong sites (HSSs 3 and 4), approximately 200 1992). The luciferase assay system was chosen because
of its sensitivity; with the conventional chloramphenicolbp apart, flanked by a third weak site (HSS 2) 1.5 kb
away. The second group was located 12±16 kb 59 of the acetyl transferase (CAT) reporter assay, no J chain pro-
moter activity could be detected with a promoter-alonetranscriptional start site and consisted of three sites
(HSSs 5±7) of medium DNase I sensitivity, roughly equiv- construct, whereas with the luciferase assay, values of
1000 and 10,000 relative light units (RLU) were obtainedalent to that displayed by the promoter HSS 1 site.
in J chain±negative and J chain±expressing B cells, re-
spectively. As these baseline values were reliably greaterDevelopment of Four of the Six HSSs (3±6)
Correlates with J Chain Gene Expression than those (200±500 RLU) of mock or basic vector trans-
fections, it was possible to quantitate any enhancer-To assess the relationship between the hypersensitive
sites and J chain gene transcription, the assays were induced increase in promoter activity.
For the analyses of the HSSs 3 and 4 sequences, a 4extended to J chain±negative cell lines representative
of immature and mature B cells and helper T cells. The kb Sau3AI±SpeI fragment containing the two sites was
subjected to systematic 59 and 39 deletions (Figure 3).resulting Southern blots showed a strong association
IL-2 Induction of the J Chain Gene Enhancer
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Figure 2. Characterization of DNase I HSSs of the J Chain Gene
(A and B) Development of DNase I HSSs 3, 4, 5, and 6 correlates with J chain gene expression. Nuclei from J chain±negative B and T cell
lymphomas and from J chain±positive myelomas were digested with DNase I for the times indicated. The DNA was extracted and assayed
on Southern blots for the presence of (A) HSSs 1±6 and (B) HSS 7 by the procedures described in the legend to Figure 1.
(C) An IL-2 signal opens the chromatin structure of the J chain gene. Nuclei were isolated from BCL1 cells cultured for 2 days in the presence
and absence of IL-2 and digested with DNase I as indicated; DNA was extracted and then digested with BamHI. The Southern blot was
hybridized with the BamHI±DraI probe from the 59 end of the BamHI 8.2 kb fragment.
The fragments generated were inserted in both orienta- was assessed following transient transfection of the
construct into S194 cells. In contrast to the HSSs 3tions 59 to the J chain promoter sequence, and the
resulting constructs were assessed for enhancer activity and 4 sequence, that associated with HSSs 5 and 6
displayed no enhancer activity (data not shown). Theby transient transfection into J chain±expressing S194
myeloma cells. Assays of the inserts in 59-to-39 orienta- average luciferase RLU was 1.4 times the RLU value
obtained for the J chain promoter alone. This findingtion showed that HSSs 3 and 4 were associated with
a sequence that amplified the activity of the J chain indicated that the correlation between the development
of HSSs 5 and 6 and J chain gene expression is likelypromoter 16- to 23-fold (Figure 3). This amplification
was one-tenth that provided by a 1 kb insert containing to represent some other transcriptional control, such as
a boundary element or LCR.the full m heavy-chain intron enhancer (Figure 3) and
was roughly equivalent to that provided by the k chain
intron enhancer (data not shown). The 1.1 kb NdeI±NheI Characterization of the J Chain Gene Enhancer
The properties of the J chain gene enhancer sequencesfragment was found to be the smallest sequence that
provided full enhancement. Any further reduction in size, containing HSSs 3 and 4 were defined by comparing
their activities in J chain±silent and J chain±expressingeither 59 or 39, resulted in a significant loss in activity
(Figure 3). Assays of the inserts in 39-to-59 orientation lymphoid cell lines (Table 1). Transient transfection
assays showed that none of the enhancer plasmid con-gave a similar pattern of activities, except that the ampli-
fication in each case was 20%±30% less (data not structs was capable of activating the J chain promoter
in T cell, immature B cell, or mature B cell lines, inshown).
For analyses of the function of HSSs 5 and 6, a 4.5 which the genomic J chain enhancer retains a closed
chromatin structure. On the other hand, the enhancerkb SpeI±XhoI fragment containing the two sites (Figure
1) was inserted 59 to the J chain promoter and its activity constructs were functional in all plasmacytomas, such
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Table 1. Specificity of J Chain Gene Enhancer Activity
Test Construct
Lymphoid Cell Linesa
J Chain negative J Chain Positive
Enhancer Promoter EL4 WEHI231 K46R S194 MPC11 MOPC315
JE4.0kb J 1.0b 1.1 1.1 23 7 83
JE1.8kb J 1.0 1.4 1.6 16 8 51
JE1.1kb J 1.8 1.2 1.3 19 10 51
JE0.5kb J 1.7 1.5 1.4 5.0 4 16
JE4.0kb Fos 2.2 ND ND 9.1 ND ND
JE1.8kb Fos 2.1 ND ND 8.6 ND ND
Em1.0kb J 1.0 9.5 16 203 98 110
ND, not determined.
a EL-4 is a T cell line; WEHI231 and K46R are lymphoma lines representative of immature and mature B cells, respectively; S194, MPC11, and
MOPC315 are plasmacytoma lines.
b Fold increase over the activity of the J chain or the Fos promoter alone. Each value represents the average of at least two independent
determinations.
as S194 (Table 1), in which the genomic J chain enhancer relative availability of transcription factors contributing
and promoter have an open chromatin conformation to enhancer activity. In any case, the data clearly indi-
and the J chain is expressed. These results might be cate that the J chain enhancer associated with HSSs 3
explained in several ways. The test plasmids could have and 4 is B cell specific and stage specific in its activity.
assumed the chromatin structure of the endogenous The 4.0 and 1.8 kb enhancer sequences were also
enhancer and promoter and behaved accordingly in the tested in the context of a heterologous promoter ex-
various cell types. Alternatively, the test plasmids could pressed in many cell types. For these experiments, plas-
have retained an open conformation but have been un- mids were constructed with the enhancer fragments
able to function in J chain±negative lymphoid cells be- located 59 to a minimal c-fos promoter and the luciferase
cause a critical transcription factor(s) was lacking. The gene. The c-fos construct contained only a TATA box
latter explanation is consistent with the variation in en- and a single CREB (cAMP response element binding
hancer activity observed among the plasmacytoma cell protein) element (Gilman et al., 1986) and gave baseline
lines. The enhancer construct was four times as active values comparable to those of the J chain promoter
in MOPC315 and one half as active in MPC11 cells as construct in B cell transient transfections. Although the
in the transfection standard S194 cells (Table 1). Since transfection assays showed that the J chain enhancer
control transfections showed that the differences in ac- was capable of transactivating the c-fos promoter in
tivity could not be attributed to differences in transfec- plasmacytomas, the amplification was only one half that
tion efficiency, it seemed likely that they reflected the seen in the context of the J chain promoter. This differ-
ence suggested that cooperative interactionsmay occur
between factors binding to the enhancer and the J chain
promoter to effect a higher level of activation.
Sequence and In Vivo Footprinting Analyses
Sequence analyses of the 1.1 kb NdeI±NheI enhancer
fragment revealed that the potential consensus se-
quences for factor binding were concentrated within a
150 bp region surrounding the PstI site. This region
included a STAT5, an Ets (a family of Ets domain proteins
related to avian erythroblastosis virus E26 transforming
specific gene), a C/EBP (CCAAT-enhancer binding pro-
tein), and two CBF (core binding factor) consensus bind-
ing sites; two consensus E2 boxes; and an 8/9 match
to the nuclear factor kB (NF-kB) consensus sequence
(Figure 4A). One additional CBF consensus site and a
STAT3 consensus site were found near the 59 end and
39 end of the 1.1 kb NdeI±NheI fragment, respectively.
Figure 3. Sequences Containing HSSs 3 and 4 Function as En- Although both the 59 and 39 sides of the 1.1 kb en-
hancers of J Chain Gene Expression hancer fragment were necessary for full enhancer activ-
A 4 kb Sau3AI±SpeI fragment containing HSSs 3 and 4 was sub- ity, the core 0.5 kb ScaI fragment containing theconcen-
jected to successive 59 and 39 deletions. The fragments generated trated consensus sites was explored first to analyze the
were examined for their ability to activate the J chain gene promoter relationship of the various potential regulatory elements
by transient transfection±luciferase assays in J chain±expressing
to enhancer activity by dimethyl sulfate (DMS) in vivoS194 myeloma cells. The mean enhancer activities (6 SEM) were
footprinting assays. Using the gene-specific primers in-calculated from the average values of at least two independent,
duplicate determinations of luciferase activity. dicated in Figure 4A, more than 0.5 kb of DNA sequence
IL-2 Induction of the J Chain Gene Enhancer
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Figure 4. Sequence and In Vivo Footprinting Analyses for the J Chain Gene Enhancer
(A) The sequence of a 1.1 kb NdeI±NheI J chain gene enhancer. The core 150 bp sequence containing a concentration of potential consensus
factor binding sites was indicated by capital letters, with flanking sequences by lower-case letters. The potential consensus sequences are
boxed. Primers used for in vivo footprinting experiments are indicated by arrows (NPs 1±3 for the noncoding strand and CPs 1±3 for the
coding strand).
(B) DMS in vivo footprinting of the noncoding and coding strands of the core enhancer sequence shown in (A). Footprints were detected only
in the DNA from J chain±positive S194 cells; the G residues in and around the E2 boxes were protected on both strands, those in the CBF
site on the noncoding strand.
(C) An IL-2±induced in vivo DNase I footprinting over the STAT5 site in BCL1 cells. Lane G is a DMS in vivo footprinting reaction of a naked
S194 DNA.
in the middle of the 1.1 kb J chain enhancer was investi- and C/EBP sites are consensus-like, no protein binding
was observed in our in vivo footprinting experiments.gated. Analyses of the DNA from two cell lines with an
inactive J chain gene enhancer, the EL-4 T cell lym-
phoma and the K46R mature B cell lymphoma, did not
reveal any detectable footprints over the sequence IL-2 Regulation of STAT5 Binding to the
J Chain Enhancertested. The pattern of G reactivity was essentially identi-
cal to that of naked DNA (Figure 4B). In contrast, four Because IL-2 was shown to induce expression of the J
chain gene by opening of the chromatin structure of theclear footprints were observed within the consensus-
clustered 150 bp region from S194 myeloma cells where J chain enhancer in BCL1 cells (Figure 2C) and because
a STAT5 consensus site was identified within the J chainthe J chain gene enhancer is active: two over the E2
boxes on both the coding and noncoding strands and enhancer (Figure 4A), a possible role of IL-2±inducible
STAT5 (Hou et al., 1995) in the process was investigated.two over the CBF sites on the noncoding strand (Figure
4B). No in vivo footprint other than those seen within To do so, the in vivo footprinting experiment was per-
formed in IL-2±induced BCL1 cells. DNase I in vivo foot-the 150 bp core region was detected over the more than
500 bp region. Although the putative G-rich NF-kB, Ets, printing was used because it was not possible to obtain
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definitive evidence for factor binding by the DMS meth- terminal B cell development and then maintain its ex-
pression constitutively in the absence of IL-2 and STAT5od, with only one G residue present on either strand in
the STAT5 sequence (TTCTATGAA). An induced foot- stimulation.
print over this STAT5 sequence was detected in the IL-
2±treated BCL1 cells (Figure 4C), although one strong Role of STAT5 in IL-2±Induced Enhancer Activity
band in the middle of a footprinted STAT5 sequence
A regulatory role for STAT5 was confirmed by mutating
remained. This pattern of footprint might be a character-
the STAT5 motif of the JE1.1kb plasmid and measuring
istic of STAT5 binding. The E2 and CBF sites were also the effect of the mutation on enhancer activity in the
footprinted in IL-2±treated BCL1 cells, although the foot- presence or absence of IL-2. The substitutions (TTCTAT
prints were weak and not as prominent as in S194 cells GAA to caCTATGtc), previously shown to abrogate bind-
(data not shown). However, E2 and CBF turned out to ing of STAT5 to the FcgRI GAS motif (Hou et al., 1995),
be not the IL-2±induced factors in our electrophoretic were also demonstrated to abrogate its binding to the
mobility shift assay (EMSA) analyses (discussed below). STAT5 motif of the J chain enhancer in our EMSA analy-
EMSA was employed to verify factor binding to the ses (data not shown). The STAT5 mutant construct was
footprinted motifs and to examine the effect of IL-2 stim- transfected into BCL1 cells and compared with the wild-ulation on factor content and its binding. For these ex- type counterpart for their ability to induce the enhancer
periments, nuclear extracts were prepared from unstim-
with or without IL-2 treatment. The STAT5 mutant con-
ulated J chain±negative BCL1 cells and IL-2±stimulated J struct resulted in an about 80% loss in its ability to
chain±positive BCL1 cellsand assayed for factor content induce the enhancer in the presence of IL-2, compared
and binding, using as probes the E2, CBF, STAT3, and
with that of wild-type control (Figure 6). This STAT5
STAT5 motifs from the enhancer sequences. No IL-2±
mutant effect is believed to be caused by a failure of
related differences were observed in the binding of E12/ STAT5 to bind to the mutated sequence, since STAT5
E47 (Murre et al., 1989), CBF (Speck and Stacy, 1995), was shown to be the only IL-2±induced binding activity
or STAT3 to their respective probes (Figures 5A±5C). In on the site in EMSA analyses (Figure 5D).
each case, the complexes formed with extracts from
untreated or IL-2±treated cells were equivalent in inten-
Discussionsity and mobility. Interestingly, the STAT3 motif (TTCCA
GTAA) found near the 39 end of the 1.1 kb enhancer
In the present study, the long-suspected J chain genefragment was shown not to have cross-binding activity
enhancer was identified as a 1.1 kb sequence locatedwith the STAT5 motif (TTCTATGAA) of the core region
7±8 kb upstream of the J chain gene start site. The(data not shown). Furthermore, to our surprise, the
identification was made by correlating the developmentSTAT3 binding activity was present constitutively in the
of hypersensitive sites in the flanking sequences with JBCL1 cells regardless of IL-2 treatment (Figure 5C).
chain gene transcription, and assaying the hypersensi-A clear difference was observed, however, in the bind-
tive sequences for enhancer function following transienting pattern of the STAT5 element present within the
transfection. Of the five strong hypersensitive sites ob-150 bp core region (Figure 5D). Two slowly migrating
served, only a 1.1 kb sequence containing two of thecomplexes were generated with extracts from IL-2±
sites, HSSs 3 and 4, met the criteria of an enhancer bystimulated cells but not from unstimulated cells (Figure
producing, independently of its orientation, a 10- to 50-5D, lanes a and b). The factors responsible for the new
fold increase in J chain promoter activity. Structuralcomplexes were identified as STAT5 proteins by several
analyses suggested that the 1.1 kb J chain enhancer iscriteria. Both complexes were specifically inhibited by
organized similarly to the heavy-chain intron enhancera 100 molar excess of the classic GAS (interferon-g±
(Forrester et al., 1994). It contains a 150±200 bp coreactivated sequence) element from the Fcg receptor I
element with multiple binding sites for transcription fac-(FcgRI) gene (Hou et al., 1995), but not by a 100 molar
tors and AT-rich flanking sequences that may representexcess of an irrelevant oligonucleotide sequence (Figure
MARs. However, transgenic experiments will be re-5D, lanes c and d). Both complexes were supershifted
quired to characterize the flanking sequences and toby the addition of a rabbit antiserum specific for the
determine whether they provide control regions, MARs,murine STAT5a and STAT5b proteins, but not by preim-
and/or LCRs, as their counterparts in the heavy-chainmune rabbit serum (Figure 5D, lanes e and f).
intron enhancer do (Forrester et al., 1994; Jenuwein etFinally, the presence of a phosphorylated and active
al., 1997). Alternatively, the more distant DNase I hyper-STAT5 protein was further assessed by Western blot
sensitive sequences, HSSs 5, 6, and 7, may serve toanalysis of nuclear extracts. A phosphorylated form of
mark an LCR, as is the case for the heavy-chain 39STAT5 was detected in the IL-2±treated BCL1 cells (Fig-
enhancer (Madisen and Groudine, 1994).ure 5E, lanes 2 and 5), but not in untreated BCL1 cells
The activity of the J chain gene enhancer was found(Figure 5E, lane 1), well correlating with their binding
to be B cell±specific and strictly confined to the antigen-activities as shown by EMSA analysis (Figure 5D). Sur-
driven stage of B cell differentiation. The evidence wasprisingly, however, the phosphorylated STAT5 was not
obtained froma combination of DNase Ihypersensitivity,detected in the J chain±expressing S194 and MOPC315
in vivo footprinting, and in vivo functional assays. Suchplasma cells (Figure 5E, lanes 3 and 4). EMSA analysis
analyses showed that the enhancer was in an inactivealso confirmed the absence of STAT5 binding activity
state in J chain±negative B cell lines, representative ofin these plasma cells (data not shown). There are numer-
early antigen-independent stages. The DNA was pack-ous possible explanations of these results. One possibil-
aged in a closed conformation that did not allow detect-ity is that the plasma cells have passed the IL-2 required
stage for induction of J chain gene expression during able factor interaction. In contrast, the enhancer was
IL-2 Induction of the J Chain Gene Enhancer
291
Figure 5. IL-2 Regulation of Factor Content
and Binding to the J Chain Gene Enhancer
(A) IL-2±independent binding of E12/E47.
EMSA analysis of the complexes formed with
BCL1 nuclear extracts and an E2 oligonucleo-
tide from the J chain gene enhancer. Lanes:
(a) extract from untreated cells; (b±d) extracts
from IL-2±treated cells (b) in the absence of
antibody and in the presence of (c) anti-E12
antibody and (d) anti-E47 antibody.
(B) IL-2±independent binding of CBF. EMSA
analysis of the complexes formed with BCL1
nuclear extracts and a CBF oligonucleotide
from the J chain gene enhancer. Lanes: (a)
extract from untreated cells; (b±f) extracts
from IL-2±treated cells (b) alone, (c±f) in the
presence of (c) a 100 molar excess of irrele-
vant oligonucleotide, (d) a 100 molar excess
of the CBF oligonucleotide from the T cell
receptor b enhancer (Wotton et al., 1994), (e)
preimmune rabbit serum, and (f) anti-CBFb2
antibody (Lu et al., 1995).
(C) IL-2±independent binding of STAT3.
EMSA analysis of the complexes formed with
BCL1 nuclear extracts and a STAT3 oligonu-
cleotide from the J chain gene enhancer.
Lanes: (a and b) extract from untreated cells
(a) in the absence of antibody and (b) in the
presence of anti-STAT3 antibody; (c±e) ex-
tracts from IL-2±treated cells (c) in the ab-
sence of antibody and in the presence of (d)
anti-STAT3 antibody and (e) anti-STAT5 anti-
body. NS, nonspecific binding complex.
(D) IL-2±dependent binding of STAT5. EMSA
analysis of the complexes formed with BCL1
nuclear extracts and a STAT5 oligonucleotide
from the J chain gene enhancer. Lanes: (a)
extract from untreated cells; (b±f) extracts
from IL-2 treated cells (b) alone, (c±f) in the
presence of (c) a 100 molar excess of an irrel-
evant oligonucleotide, (d) a 100 molar excess
of the GAS oligonucleotide from the FcgRI
promoter (Hou et al., 1995), (e) preimmune
rabbit serum, and (f) anti-STAT5b antibody
that is specific for both STAT5a and STAT5b.
NS, nonspecific binding complex.
(E) Western blot analysis for STAT5 in the nu-
clear extracts of BCL1, S194, and MOPC315.
Two bands indicative of unphosphorylated a
and bisoforms were detected in IL-2±untreated
BCL1, S194, and MOPC315 cells, whereas a
new band indicative of a phosphorylated form
of STAT5a and/or STAT5b was detected on
top of those two bands only in IL-2±treated
BCL1 cells. Lane 5 is from another blot with
a short chromogenic reaction time.
switched to an active state in cell lines representative obtained from analyses of the IL-2 responsive prese-
cretor line, BCL1. IL-2 stimulation of these cells inducedof various J chain±positive plasma cell stages. The chro-
matin structure was opened to allow factor binding and two enhancer-related changes: opening of the chroma-
tin structure and phosphorylation of the STAT5 tran-consequent J chain gene transcription. To our knowl-
edge, the J chain gene enhancer is the only known scription factor and its binding to the enhancer motif.
The importance of the STAT5 interaction was estab-lymphoid enhancer to exhibit such a limited pattern of
activity. This pattern means that the enhancer may pro- lished by the 80% loss in enhancer inducibility that fol-
lowed a mutation of the STAT5 element. These datavide a useful tool for limiting the expression of trans-
fected genes to the antigen-driven stage of B cell differ- provide the first example of IL-2±dependent STAT5 gene
regulation in B cells. The related regulation of the IL-2entiation and thus for analyzing the contribution of such
genes to the B cell immune response. receptor a chain (IL-2Ra) is likely to provide another
such example. Recent studies have shown that tran-In addition to characterizing the J chain gene en-
hancer, the present study demonstrated that IL-2 deliv- scription of the IL-2Ra gene in T cells is initiated by IL-1
or antigen stimulus and subsequently up-regulated anders the ªonº signal to the enhancer. The evidence was
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to lead to a transcriptionally permissive chromatin struc-
ture, such as histone acetylation (Brownell and Allis,
1996; Ogryzko et al., 1996) or release of a topologically
restrained chromatin domain (Cai and Levine, 1995;
Corces, 1995). These possibilities need to be explored
further. However, recent reports that STAT1 and STAT2
recruit CBP/p300 (Bhattacharya et al., 1996; Zhang et
al., 1996; Horvai et al., 1997; Montminy, 1997) might be
interesting because CBP/p300 was shown to have a
histone acetyltransferase (HAT) activity (Ogryzko et al.,
1996), which is involved in the regulation of chromatin
structure (Grunstein, 1997). In these regards, we specu-
late that IL-2 signaling might be transduced throughFigure 6. STAT5 Element Is Critical for the IL-2 Induction of J Chain
the binding of a phosphorylated STAT5 to the J chainGene Enhancer
enhancer and result in the opening of chromatin by re-The 1.1 kb enhancer plasmid containing clustered mutations in the
STAT5 element (STAT5M) was electrotransfected into BCL1 cells cruiting a HAT activity±containing CBP/p300-like pro-
and compared with the wild-type plasmid (WT) for their ability to tein. Moreover, a chromatin-directed signal could help
induce the luciferase expression in the presence or absence of IL-2. toexplain the regulatory mechanismsof othercytokines,
The luciferase activities obtained are expressed relative to the value
such as IL-4, that are known to induce chromatinobtained with the wild-type enhancer in the absence of IL-2, which
changes in their gene targets (Berton and Vitetta, 1990).was set to 1. The values given represent the average of six indepen-
dent determinations, and the calculated SEMs are represented by
error bars. Experimental Procedures
Cell Culture
The cell lines were maintained at 378C in Dulbecco's modified Ea-maintained by an IL-2 stimulus (Sperisen et al., 1995).
gle's medium or RPMI 1640 supplemented with 10% fetal bovineIL-2 responsiveness maps to an upstream enhancer that
serum, 2 mM L-glutamine, 0.1 mM MEM nonessential amino acids,
contains a STAT element and depends on STAT5 bind- 1 mM MEM sodium pyruvate, 50 mM 2-mercaptoethanol, 100 U/ml
ing for its activity (Sperisen et al., 1995; Lecine et al., penicillin G, and 100 mg/ml streptomycin in an atmosphere of 7%
1996). Since the a chain is required for the formation of CO2 saturated with water. For the BCL1 chromatin experiments, 35
ml of recombinant IL-2 (28 Takeda U/ml 5 1 mg/ml [Takeda Chemicalthe high-affinity receptor that mediates IL-2 signaling in
Industries]) were added to a 70 ml culture of early logarithmic-phaseB cells as well as T cells, the mechanisms regulating a
cells on day 1 and an additional 35 ml of IL-2 on the next day. Cellschain expression would be expected to be the same in
were harvested for DNase I hypersensitivity assay on day 3, whenthe two cell types. Moreover, the requirement of a high-
the concentration of cells was approximately 5 3 105/ml.
affinity receptor for effective IL-2 signaling explains why
the activity of the J chain gene enhancer is limited to DNase I Hypersensitivity Assay
the antigen-driven stages of B cell development. Cells in logarithmic-phase growth (0.5±1.0 3 106/ml, 85 ml) were
Studies of the mechanism of IL-2 regulation of B cell harvested by centrifugation and then allowed to swell in 10 ml of
hypotonic solution (10 mM Tris-HCl [pH 7.9], 10 mM KCl, 3 mMimmune responses have identified several nuclear out-
dithiothreitol, 0.1 mM EDTA, 0.1 mM EGTA, 0.75 mM spermidine,comes of the IL-2 signal. They include the activation of
0.15 mM spermine) for 20 min on ice. Triton X-100 was added to athe J chain gene enhancer and the likely activation of
final concentration of 0.1%, and the cell membranes were broken
the IL-2Ra chain enhancer (discussed above), as well by 20 strokes with a B pestle in a Dounce homogenizer. After the
as the activation of the J chain gene promoter (Rinken- homogenate was centrifuged at 48C for 7 min at 1500 rpm, the
berger et al., 1996) and the heavy-chain 39 enhancer pelleted nuclei were resuspended in 2.5 ml of DNase I digestion
buffer (0.25 M sucrose, 60 mM KCl, 15 mM NaCl, 15 mM Tris-HCl(J. J. Wallin and M. E. K., unpublished data). In each
[pH 7.5], 5 mM MgCl2, 1 mM CaCl2, 0.5 mM dithiothreitol, 0.1 mMcase, the IL-2 signal has been shown to induce a change
EGTA, 5% glycerol). For the zero time point in the assay (the DNasein transcription factor expression: the activation of
I untreated control), 500 ml of the nuclear suspension was removed
STAT5 for the J chain and IL-2Ra chain enhancer func- and added to 50 ml of quenching solution (200 mM EDTA, 10% SDS).
tions (this report and Lecine et al., 1996) and the de- Five units of DNase I (1 U/ml, 0.5 mg/ml) were then added to the
crease in BSAP expression to relieve the inhibition of remaining 2 ml; the suspension was mixed well at room temperature;
and the digestion was stopped at time points of 0.5, 1, 2, and 3 minthe J chain promoter (McFadden and Koshland, 1991;
by transferring 500 ml samples to 50 ml of quenching solution. TheRinkenberger et al., 1996) and 39 heavy-chain enhancer
quenched viscous DNA samples were treated with 20 ml of RNasefunctions (Neurath et al., 1995). In each case, the IL-2
A (10 mg/ml) for 30 min at 378C and then with 18 ml of proteinase
signal has also been shown to induce an opening in the K (20 mg/ml) overnight at 558C. The DNA was purified by phenol-
chromatin structure of the target promoter or enhancer chloroform extraction and ethanol precipitation, digested with ap-
(Minie and Koshland, 1986; Giannini et al., 1993; Soldaini propriate restriction enzymes, and analyzed in Southern blots.
Southern blots (Zeta-Probe, Bio-Rad) were performed with randomet al., 1995).
primer-labeled probes as described (Sambrook et al., 1989).The question then arises as to whether the binding of
STAT5 and the loss in BSAP binding are responsible
Isolation of J Chain Gene 59 Flanking Sequencesfor the chromatin changes, or alternatively, whether a
Two overlapping DNA sequences containing the six upstream HSSssecond, as yet unidentified, target of the IL-2 signal
described in this report were isolated by screening mouse genomic
generates the open DNA structure that allows regulation libraries. One was obtained by probing the T cell hybridoma library
by STAT5 and BSAP. Such a second signal could func- 1.9.2 (a generous gift from A. Winoto) with J chain cDNA. The second
was obtained by probing a mouse BALB/c liver library (ML1030j,tion by activating any one of several processes known
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Clontech) with a 165 bp BamHI±DraI fragment, described in the For IL-2±induced in vivo DNase I footprinting in BCL1 cells, cells
grown on a 150 mm plate were treated for 3 hr with IL-2 (28 Takedalegend to Figure 1.
U/ml). The cells were swelled by replacing media with 10 ml of the
described hypotonic solution supplemented with Na3VO4 (1 mM)Plasmid Constructions for Enhancer Analyses
and okadaic acid (0.25 mM) for 7 min, and the cell membranes wereThe plasmids for testing J chain enhancer activity were constructed
broken by 15 strokes with a B pestle in a Dounce homogenizer.by inserting either a J chain promoter DNA fragment (21153 to 133)
After the homogenate was centrifuged at 48C for 3 min at 1800 rpmor a minimal c-fos promoter (271 to 1109) into the BamHI and/or
(Sorvall RT6000B), the pelleted nuclei were resuspended in 2 ml ofHindIII sites at the 39 end of the polylinker in the pGL2-Basic lucifer-
the described DNase I digestion buffer and treated with 50 U of DNasease reporter vector (Promega). Restriction enzyme fragments con-
I for 30 s. The digestion was stopped by adding 250 ml of thetaining the DNase I hypersensitive sites, and thus potential en-
quenching solution. The DNA was prepared as in the DNase I hyper-hancers, were inserted at the 59 end of the plasmid polylinker as
sensitivity assay and modified at the 39-OH ends for LM-PCR asfollows: the Sau3AI±SpeI (4 kb), EcoRV±SpeI (1.8 kb), and ScaI (0.5
described (Tanguay et al., 1990).kb) fragments were cloned in the SmaI site in both orientations; the
LM-PCR was performed using 2.5±5 mg samples of the purifiedNdeI±NheI (1.1 kb) and the ScaI±NheI (0.8 kb) fragments were cloned
DNA. The primers for the noncoding strand were as follows: NP1 forinto the vector SmaI and NheI sites in 59-to-39 orientation; and the
first-strand synthesis, CCCAATGAAGTTTGGAAGTAGACCAC; NP2NdeI±ScaI insert (0.8 kb) was made by deleting the 297 bp ScaI±NheI
for amplification of ligated DNA, AAGTAGACCACTTGTCGATTAGGfragment from the NdeI±NheI insert. As a positive control, the 1 kb
ACC; and NP3 for labeling, TTGTCGATTAGGACCTGTGGGTAATGG.XbaI fragment of the immunoglobulin heavy-chain intron enhancer
The equivalent primers for the coding strand were: CP1, GGGTATCwas cloned into the unique BamHI site 39 of the luciferase reporter.
AGACAGCAAAATCTTAAATC; CP2, TCTTAAATCTAAAAAGAACTCThe structures of all constructswere confirmed by restriction digests
AAAACATAG; and CP3, AAAGAACTCAAAACATAGGGAGAAACC.and/or sequencing.
Vent(exo2) DNA polymerase (New England Biolabs) was used in theMutagenesis of the pGL2 plasmid containing the 1.1 kb NdeI±NheI
PCR with the supplied Thermopol buffer so that it was necessary toenhancer insert was performed with a site-directed mutagenesis kit
calculate the melting temperature for each primer using the formula(Transformer, Clontech). A gene-specificprimer, 59-CCCAATAGCAA
given by Ausubel et al. (1994). To optimize the LM-PCR reactions,CACTATGTCAAGCCACTGCAGG-39, was used to introduce the indi-
the DNA was purified by a combination of phenol-chloroform extrac-cated 4 bp changes into the STAT5 element of the J chain enhancer.
tion and ethanol precipitation, after both the first-strand synthesisA selection primer, 59-CTTATCATGTCTAGATCTGTCGACCGATG-
and the ligation reaction.39, was used to introduce the indicated 2 bp changes that converted
the unique BamHI site 39 of the luciferase reporter to a BglII site.
Electrophoresis Mobility Shift AssayThe generated mutant was verified by sequencing.
The nuclear extracts for EMSA were prepared basically according
to the methods described (Dignam et al., 1983; Shapiro et al., 1988).Transient Transfections and Luciferase Assays
The modifications included washing of the nuclei through a 30%Transient transfections of all cell lines except BCL1 were performed
sucrose cushion; addition of PMSF (0.5 mM), aprotinin (125 mg/by the DEAE-dextran technique (Grosschedl and Baltimore, 1985).
ml), leupeptin (125 mg/ml), and pepstatin A (20 mg/ml) to inhibitIn each case, 0.5±1.0 3 107 cells in logarithmic growth phase were
proteases; and addition of 1 mM sodium vanadate to inhibit phos-transfected with 0.5 pmol (2.2±3.5 mg) of supercoiled test plasmid.
phatase activity. To measure the effect of IL-2 stimulation on factorAfter 2 days of incubation at 308C, the cells were harvested and
binding to the enhancer, nuclear extracts were prepared from BCL1analyzed for luciferase activity using Analytical Luminescence Labo-
cells exposed to recombinant IL-2 (1.25±14 Takeda U/ml) for 0.5±20ratory equipment and reagents (Enhanced Luciferase Assay Kit).
hr at 378C.The protein content of the cell extracts was determined by Bradford
EMSA was performed as described previously (Rinkenberger etassay (Bio-Rad).
al., 1996) by electrophoresis through glycerol-containing 5% poly-Transient transfection of BCL1 cells was performed by electropor-
acrylamide gels (29:1) containing 0.253 Tris-borate-EDTA buffer.ation as follows. Cells were harvested from two 150 mm confluent
For the antibody blocking and/or supershift assays, nuclear extractsplates by pipetting up and down during two phosphate-buffered
were preincubated for 15 min with 1 ml (0.1 mg) of anti-STAT5b (sc-saline (PBS) washes and one final RPMI 1640 wash, and resus-
835) or anti-STAT3 (sc-482) rabbit polyclonal IgG (Santa Cruz); or 1pended in 1.2 ml RPMI 1640. A 300 ml aliquot of the cell suspension
ml of an undiluted anti-CBFb2 rabbit polyclonal antibody (a generouswas used for each transfection with 2 pmol (10 mg) of the test
gift from Y. Ito); or 2 ml of undiluted mouse monoclonal anti-E12 orplasmid. The electroporation was performed at room temperature
anti-E47 antibody (a generous gift from C. Murre). Oligonucleotideusing a Bio-Rad Gene Pulse Apparatus with a 0.4 cm cuvette. After
sequences from the J chain gene enhancer used as probes werepulsing at settings of 960 mF and 300 V, 1 ml of RPMI 1640 supple-
as follows: 59 E2 box, ctagATGAAAAGCCACTGCAGGTGCAAGTTTmented with serum and additives as noted above was added imme-
ATT; 39 CBF site, gatcAAACATTTTAACCACAAGCCTGCCCTAAG;diately to the cuvette and then transferred to 100 mm plate with or
STAT3 site, CCATGATTCCAGTAATTCAG; and STAT5 site, gatcCAAwithout IL-2 (14 Takeda U/ml). The transferred cells were initially
TAGCAATTCTATGAAAAGCCACTG.cultured at 378Cfor 1±3 hr andthen at 308Cfor 19±22 hr for luciferase
expression.
Western Blot
Nuclear extracts (2.5 mg) prepared as described above were re-In Vivo Footprinting via Ligation-Mediated PCR
solved by 8% SDS-PAGE and transferred to the nitrocellulose mem-DMS in vivo footprint analysis by ligation-mediated (LM) PCR was
brane. The blot was then analyzed using anti-STAT5b (C-17), whichperformed as described (Ausubel et al., 1994) with the following
is specific for both STAT5a and STAT5b (Santa-Cruz, sc-835), andmodifications. For the preparation of the DNA, 70 ml of cells in
alkaline phosphatase±conjugated anti-rabbit IgG (Promega, S3731).logarithmic-phase growth (0.5±1.0 3 106 cells/ml) were pelleted and
resuspended in 2 ml of the same media used for cell culture. The
Acknowledgmentsresuspended cells were mixed with 20 ml of 10% DMS (in ethanol)
and incubated at room temperature for 2±5 min. The reaction was
We are very grateful to C. Murre for providing the monoclonal anti-stopped by adding 3 ml of 2-mercaptoethanol (1 M) and then 20 ml
bodies for E12 (382.6) and E47 (34.1) and to Y. Ito for the generouscold PBS. After the cells were collected by centrifugation in the
gift of rabbit anti-CBFb2 antibodies. We also thank A. Winoto andcold, they were washed once with 40 ml of cold PBS, resuspended
W. Sha for their helpful discussions. This work was supported in partin 2 ml of cold PBS, and lysed by adding 250 ml of quenching solution
by Public Health Service grant A107079 from the National Instituteof(200 mM EDTA, 10% SDS, 50 mM EGTA). The lysed cells were
Allergy and Infectious Disease and in part by a grant from the Kecktreated with 100 ml of RNase A (10 mg/ml) for 30 min at 378C and
Foundation.then with 90 ml of proteinase K (20 mg/ml) overnight at 558C. The
DNA was purified and treated with 1 M piperidine as described by
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